公开(公告)号：US20170042880A1

公开(公告)日：2017-02-16

申请号：US15305854

申请日：2015-04-27

Applicant: Exelixis, Inc.

Inventor： Dana T. Aftab ,  Peiwen Yu

IPC: A61K31/47 ,  C12Q1/68

CPC classification number: A61K31/47 ,  A61K31/337 ,  A61K31/517 ,  A61K31/7068 ,  C12Q1/6886 ,  C12Q2600/158 ,  A61K2300/00

Abstract: This invention is directed to the treatment of cancer in a patient, particularly a patient with lung adenocarcinoma, and more particularly a patient with SLC34A2-ROS1, CD74-ROS1, or FIG-ROS1 fusion-positive non-small cell lung cancer, with an inhibitor of MET, VEGFR2, and ROS1 which is a compound of Formula (I): or a pharmaceutically acceptable salt thereof.

Abstract translation: 本发明涉及治疗患者，特别是患有肺腺癌的患者，特别是患有SLC34A2-ROS1，CD74-ROS1或FIG-ROS1融合阳性非小细胞肺癌的患者，其具有 其为式（I）化合物的MET，VEGFR2和ROS1抑制剂：或其药学上可接受的盐。

公开(公告)号：US20230301979A1

公开(公告)日：2023-09-28

申请号：US18018805

申请日：2021-07-29

Applicant: Exelixis, Inc.

Inventor： Gisela Schwab ,  Christian Scheffold ,  Colin Chong ,  Ssucheng Jeff Hsu ,  Peter Lamb ,  Peiwen Yu

IPC: A61K31/47 ,  C07K16/28 ,  A61K38/20 ,  A61K45/06 ,  A61P35/04

CPC classification number: A61K31/47 ,  C07K16/2818 ,  C07K16/2827 ,  A61K38/2013 ,  A61K45/06 ,  A61P35/04 ,  C07B2200/13

Abstract: The present invention relates to combinations comprising a checkpoint inhibitor and a c-Met inhibitor, Compound 1. The invention also relates to crystalline forms of the free base of Compound 1, as well as crystalline forms of salts of Compound 1, in combination with a checkpoint inhibitor. The invention also relates to pharmaceutical compositions comprising these combinations. The invention further relates to methods of treating cancer by administering Compound 1 as a single agent or a combination described herein.